首页> 外文期刊>Toxicology and Applied Pharmacology >Effects of diosmetin on nine cytochrome P450 isoforms, UGTs and three drug transporters in vitro
【24h】

Effects of diosmetin on nine cytochrome P450 isoforms, UGTs and three drug transporters in vitro

机译:二孔豆类对九种细胞色素P450同种型,UGTS和三种药物转运蛋白的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Diosmetin (3′, 5, 7-trihydroxy-4′-methoxyflavone), a natural flavonoid from traditional Chinese herbs, has been used in various medicinal products because of its anticancer, antimicrobial, antioxidant, estrogenic and anti-inflammatory activity. However, flavonoids could affect the metabolic enzymes and cause drug-drug interactions (DDI), reducing the efficacy of co-administered drugs and potentially resulting in serious adverse reactions. To evaluate its potential to interact with co-administered drugs, the IC 50 value of phase I cytochrome P450 enzymes (CYPs), phase II UDP-glucuronyltransferases (UGTs) and hepatic uptake transporters (organic cation transporters (OCTs), organic anion transporter polypeptides (OATPs) and Na + -taurocholate cotransporting polypeptides (NTCPs)) were examined in vitro by LC-MS/MS. Diosmetin showed strong inhibition of CYP1A2 in a concentration-dependent manner. The intensity of the inhibitory effect was followed by CYP2C8, CYP2C9, CYP2C19 and CYP2E1. For CYP2A6, CYP2B6, CYP2D6 and CYP3A4, diosmetin was found to have no significant inhibitory effects, and the induction effect on CYPs was not significant. For UGTs, diosmetin had a minimal inhibitory effect. In addition, the inhibitory effects of diosmetin on OATP and OCT1 were weak, and it had little effect on NTCP. This finding indicated that drug-drug interactions induced by diosmetin may occur through co-administration of drugs metabolized by CYP1A2. Highlights ? Diosmetin strongly inhibited CYP1A2 and moderately inhibited CYP2C8, CYP2C9, CYP2C19 and CYP2E1. ? Diosmetin had weak inhibitory effects on UGTs, OATP and OCT1. ? Diosmetin induced drug-drug interactions may occur through co-administration of drugs metabolized by CYP1A2 in the clinic.
机译:摘要Diosmetin(3',5,7-三羟基Xy-4'-Methoxyflavone)是一种来自中草药的天然类黄酮,已被用于各种药品,因为其抗癌,抗微生物,抗氧化剂,雌激素和抗炎活性。然而,黄酮类化合物可能影响代谢酶并导致药物 - 药物相互作用(DDI),降低共同施用的药物的功效,并可能导致严重不良反应。为了评估其与共同施用的药物相互作用的潜力,IC 50值的I相细胞色素P450酶(CYPS),II期UDP-葡糖醛丙烯酸转移酶(UGTS)和肝摄取转运蛋白(有机阳离子转运蛋白(OCT),有机阴离子转运蛋白多肽通过LC-MS / MS在体外检查(OATP)和Na + - 茶醇酸盐酸盐酸盐酸盐(NTCP))。 Diosmetin以浓度依赖性方式表现出对CYP1A2的强烈抑制。抑制效果的强度随后是CYP2C8,CYP2C9,CYP2C19和CYP2E1。对于CYP2A6,CYP2B6,CYP2D6和CYP3A4,发现Diosmetin没有显着的抑制作用,并且对CYP的诱导效果不显着。对于UGT,Diosmetin具有最小的抑制作用。此外,Diosmetin对OATP和OCT1的抑制作用弱,对NTCP几乎没有影响。该发现表明,Diosmetin诱导的药物 - 药物相互作用可能通过CYP1A2代谢的药物共同施用。强调 ? Diosmetin强烈抑制CYP1A2和中度抑制CYP2C8,CYP2C9,CYP2C19和CYP2E1。还Diosmetin对UGTS,OATP和OCT1的抑制作用较弱。还通过CYP1A2在临床中通过CYP1A2代谢的药物共同给予Diosmetin诱导的药物 - 药物相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号